Clinical Trial Update: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating NIS793 in combination with standard of care therapy for second-line metastatic colorectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• NIS793 (NIS-793)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: TERMINATED